ReviewDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2013
Predictive biomarkers for Barrett's esophagus: so near and yet so far.
Review in Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Epigenetic biomarkers and the progression of Barrett's oesophagus to oesophageal adenocarcinoma: a systematic review protocol.Systematic reviews · 2026Article
- Long-term outcomes of surveillance or endoscopic therapy for low-grade dysplastic Barrett's according to a selective management algorithm.Endoscopy international open · 2026Article
- Development of Advanced Imaging and Molecular Imaging for Barrett's Neoplasia.Diagnostics (Basel, Switzerland) · 2022Review
- Article
- Recurring Translocations in Barrett's Esophageal Adenocarcinoma.Frontiers in genetics · 2021Article
- Towards screening Barrett's oesophagus: current guidelines, imaging modalities and future developments.Clinical journal of gastroenterology · 2020Review
- Differential Expression Profiles of Oxidative Stress Levels, 8-oxo-dG and 4-HNE, in Barrett's Esophagus Compared to Esophageal Adenocarcinoma.International journal of molecular sciences · 2019Article
- Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus.Digestive diseases and sciences · 2018Review
- Barrett's oesophagus: Current controversies.World journal of gastroenterology · 2017Review
- Review
- Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma.Gastroenterology clinics of North America · 2015Review
- The Presence of Genetic Mutations at Key Loci Predicts Progression to Esophageal Adenocarcinoma in Barrett's Esophagus.The American journal of gastroenterology · 2015Article
- Diagnostic and Management Implications of Basic Science Advances in Barrett's Esophagus.Current treatment options in gastroenterology · 2015Article
- TissueCypher(™): A systems biology approach to anatomic pathology.Journal of pathology informatics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
Barrett's esophagus (BE) is the strongest risk factor for the development of esophageal adenocarcinoma. However, the risk of cancer progression is difficult to ascertain in individuals, as a significant number of patients with BE do not necessarily progress to esophageal adenocarcinoma. There are several issues with the current strategy of using dysplasia as a marker of disease progression. It is subject to sampling error during biopsy acquisition and interobserver variability among gastrointestinal pathologists. Ideal biomarkers with high sensitivity and specificity are needed to accurately detect high-risk BE patients for early intervention and appropriate cost-effective surveillance. To date, there are no available molecular tests in routine clinical practice despite known genetic and epigenetic aberrations in the Barrett's epithelium. In this review, we present potential biomarkers for the prediction of malignant progression in BE. These include markers of genomic instability, tumor suppressor loci abnormalities, epigenetic changes, proliferation markers, cell cycle predictors, and immunohistochemical markers. Further work in translating biomarkers for routine clinical use may eventually lead to accurate risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.